Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operation-income-chart

RXRX Operation Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for RXRX's Operation Income in Q4'25 shows a loss of $108.3M USD, marking a notable improvement from the previous quarter's $172.2M USD loss in Q3'25 and the deepest loss of $191.4M USD in Q1'25. This represents the smallest quarterly deficit in the period, with year-over-year growth of 41.0%, indicating a positive shift in operational performance. Over the timeframe from Q1'23 to Q4'25, Operation Income has exhibited a volatile yet generally deepening trend of losses, starting at $69.9M USD in Q1'23 and peaking at $183.8M USD in Q4'24 before a partial recovery in 2025. Significant declines occurred in Q3'23 (-$99.6M USD) and Q4'24, driven by factors reflected in YoY changes that fluctuated from -59.1% in Q3'23 to a brief positive +1.2% in Q3'24, followed by sharp drops exceeding -85% in Q4'24 and Q1'25. The bar chart highlights persistent negative territory, with YoY line trends underscoring operational challenges in scaling profitability amid biotech sector pressures. The overall pattern suggests improving momentum in late 2025, though sustained losses averaging around $120M USD quarterly emphasize the need for cost controls to achieve breakeven.